CN117098549A - 纳米凝胶被覆型疫苗 - Google Patents

纳米凝胶被覆型疫苗 Download PDF

Info

Publication number
CN117098549A
CN117098549A CN202280025674.XA CN202280025674A CN117098549A CN 117098549 A CN117098549 A CN 117098549A CN 202280025674 A CN202280025674 A CN 202280025674A CN 117098549 A CN117098549 A CN 117098549A
Authority
CN
China
Prior art keywords
nanogel
pro
leu
val
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280025674.XA
Other languages
English (en)
Chinese (zh)
Inventor
清野宏
幸义和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
He Na Biological Co ltd
University of Tokyo NUC
Original Assignee
He Na Biological Co ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by He Na Biological Co ltd, University of Tokyo NUC filed Critical He Na Biological Co ltd
Publication of CN117098549A publication Critical patent/CN117098549A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280025674.XA 2021-03-30 2022-03-28 纳米凝胶被覆型疫苗 Pending CN117098549A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021056392 2021-03-30
JP2021-056392 2021-03-30
PCT/JP2022/014798 WO2022210465A1 (ja) 2021-03-30 2022-03-28 ナノゲル被覆型ワクチン

Publications (1)

Publication Number Publication Date
CN117098549A true CN117098549A (zh) 2023-11-21

Family

ID=83459198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280025674.XA Pending CN117098549A (zh) 2021-03-30 2022-03-28 纳米凝胶被覆型疫苗

Country Status (8)

Country Link
US (1) US20240181033A1 (https=)
EP (1) EP4316511A4 (https=)
JP (1) JPWO2022210465A1 (https=)
KR (1) KR20230163443A (https=)
CN (1) CN117098549A (https=)
AU (1) AU2022248775A1 (https=)
CA (1) CA3212267A1 (https=)
WO (1) WO2022210465A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566516B1 (en) 1998-08-31 2003-05-20 Nof Corporation High purity polysaccharide containing a hydrophobic group and process for producing it
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
JP2020019754A (ja) * 2018-08-03 2020-02-06 国立研究開発法人農業・食品産業技術総合研究機構 ウシ乳房炎に対する粘膜ワクチン組成物

Also Published As

Publication number Publication date
AU2022248775A1 (en) 2023-10-12
US20240181033A1 (en) 2024-06-06
JPWO2022210465A1 (https=) 2022-10-06
CA3212267A1 (en) 2022-10-06
KR20230163443A (ko) 2023-11-30
WO2022210465A1 (ja) 2022-10-06
EP4316511A1 (en) 2024-02-07
EP4316511A4 (en) 2025-05-21

Similar Documents

Publication Publication Date Title
CN105126115B (zh) 二氧化硅纳米颗粒及其用于疫苗接种的用途
Lin et al. Enhanced immune responses to mucosa by functionalized chitosan-based composite nanoparticles as a vaccine adjuvant for intranasal delivery
Abd Elkodous et al. Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19
Chehelgerdi et al. Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine
KR101342641B1 (ko) 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
CN107365751B (zh) 流感疫苗的生产
KR102007278B1 (ko) 바이러스 진단 및 치료를 위한 인지능 물질 및 이의 제조방법
US10786537B2 (en) Method of inducing an oncolytic effect on tumor cells using Zika virus
US12453768B2 (en) Vaccines for in vivo expression of nucleic acids and methods of using the same
Witeof et al. Atomic-layer deposition processes applied to phage λ and a phage-like particle platform yield thermostable, single-shot vaccines
JP2020504179A (ja) 汎用インフルエンザワクチン組成物
US9833407B2 (en) Nasal vaccine for Streptococcus pneumoniae
US20200306364A1 (en) Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
CN112089834B (zh) 基于氧化石墨烯的茯苓多糖纳米佐剂及佐剂/抗原共递送疫苗的制备与应用
Debnath et al. Potential application of bionanoparticles to treat severe acute respiratory syndrome coronavirus-2 infection
CN113813375A (zh) 一种新型抗新冠病毒复合物的组成及其在防治冠状病毒感染疾病药物中的应用
CN117098549A (zh) 纳米凝胶被覆型疫苗
CN108623668A (zh) 一种新型重组蜂毒多肽及其制备方法和应用
CA2429144A1 (fr) Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur ou adjuvant
WO2021236626A1 (en) Mucoretentive antiviral technologies
US20250345282A1 (en) Extracellular vesicle comprising antigenic protein or gene encoding same protein, and uses thereof
KR20250133604A (ko) 점막 백신 조성물과 그의 사용
CN115697399A (zh) 冠状病毒感染的诊断、预防和治疗
Muthukutty et al. A multivalent 9-O-acetylated sialic acid-conjugated bacteriophage platform for antiviral and immunomodulatory therapy for human coronavirus OC43
CN120550135A (zh) 抑制流感病毒的纳米颗粒ha-adh-gl及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination